Bionano Genomics Terminates Material Agreement
Ticker: BNGO · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1411690
| Field | Detail |
|---|---|
| Company | Bionano Genomics, Inc. (BNGO) |
| Form Type | 8-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $200,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination, corporate-action
Related Tickers: BNGO
TL;DR
BNGO terminated a big deal, could be good or bad.
AI Summary
Bionano Genomics, Inc. announced on February 4, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on February 10, 2025, detailing the event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material agreement introduces uncertainty regarding the company's business relationships and financial stability.
Key Players & Entities
- Bionano Genomics, Inc. (company) — Registrant
- February 4, 2025 (date) — Date of earliest event reported
- February 10, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific material definitive agreement was terminated?
The filing states that a material definitive agreement was terminated, but does not specify which agreement in the provided text.
What is the effective date of the termination?
The earliest event reported, which is the termination of the agreement, occurred on February 4, 2025.
What are the potential consequences of this termination for Bionano Genomics?
The filing does not detail the specific consequences, but the termination of a material agreement typically impacts operations and finances.
Was this termination a mutual decision or initiated by one party?
The provided text does not specify whether the termination was mutual or unilateral.
Does this termination affect any ongoing business operations or partnerships?
The filing indicates a 'material definitive agreement' was terminated, suggesting a potential impact on business operations or partnerships, though specifics are not detailed.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-10 17:16:12
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq
- $200,000,000 — regate offering sales proceeds of up to $200,000,000 (the " Shares "), from time to time thr
Filing Documents
- ef20043253_8k.htm (8-K) — 26KB
- 0001140361-25-003762.txt ( ) — 197KB
- bngo-20250204.xsd (EX-101.SCH) — 4KB
- bngo-20250204_def.xml (EX-101.DEF) — 17KB
- bngo-20250204_lab.xml (EX-101.LAB) — 26KB
- bngo-20250204_pre.xml (EX-101.PRE) — 19KB
- ef20043253_8k_htm.xml (XML) — 6KB
02
Item 1.02 Termination of a Material Definitive Agreement. On February 4, 2025, Bionano Genomics, Inc. (the " Company "), provided notice of its termination, effective February 14, 2025, of that certain Sales Agreement, dated as of March 23, 2021, as amended March 9, 2023 (the " Sales Agreement "), by and among the Company and Cowen and Company, LLC (" Cowen "). As previously reported, pursuant to the terms of the Sales Agreement, the Company could offer and sell shares of its common stock, par value $0.0001 per share, having aggregate offering sales proceeds of up to $200,000,000 (the " Shares "), from time to time through an "at the market" equity offering program under which Cowen would act as agent and/or principal (the " ATM Program ").
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: February 10, 2025 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive and Financial Officer)